This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37415003
rdf:type
wikibase:Item
schema:description
wetenschappelijk artikel videnskabelig artikel articolo scientifico наукова стаття, опублікована в березні 2009 bilimsel makale vědecký článek научни чланак vetenskaplig artikel artículu científicu espublizáu en 2009 article scientifique مقالة علمية نشرت في 13 مارس 2009 vedecký článok scientific article published on 13 March 2009 artigo científico article científic wissenschaftlicher Artikel
p:P577
wds:Q37415003-B15F08E6-81C7-479A-9AFE-417F782130AB
wdt:P577
2009-03-13T00:00:00Z
p:P407
wds:Q37415003-B99B96E4-6CCC-429F-8F8B-71A59B60B163
wdt:P407
wd:Q1860
p:P2093
wds:Q37415003-81AD60EC-3E86-4E8F-9B14-01403C800097
wdt:P2093
Georg-Burkhard Kresse
rdfs:label
Biosimilars--science, status, and strategic perspective Biosimilars--science, status, and strategic perspective Biosimilars--science, status, and strategic perspective
skos:prefLabel
Biosimilars--science, status, and strategic perspective Biosimilars--science, status, and strategic perspective Biosimilars--science, status, and strategic perspective
schema:name
Biosimilars--science, status, and strategic perspective Biosimilars--science, status, and strategic perspective Biosimilars--science, status, and strategic perspective
p:P1476
wds:Q37415003-317FDBCD-E33D-4E10-9173-5217A94A2070
wdt:P1476
Biosimilars--science, status, and strategic perspective
p:P304
wds:Q37415003-2E963044-A654-44B6-8611-0E4A2E75EFA9
wdt:P304
479-486
p:P31
wds:Q37415003-00ff5115-a21d-4082-9ee1-da1b1e615c28 wds:Q37415003-BBE8DEF2-25A3-49FA-B112-54E7695E0A10
wdt:P31
wd:Q7318358 wd:Q13442814
p:P698
wds:Q37415003-62B9322E-D124-4150-ABFA-089636A7BDDA
wdtn:P698
n12:19286455
wdt:P698
19286455
p:P1433
wds:Q37415003-64BDD8E3-EDAF-48F8-A02F-2D3F7D8343C4
wdt:P1433
wd:Q5412740
p:P433
wds:Q37415003-3D008069-30AF-4A07-B883-EB96DB2577EB
p:P478
wds:Q37415003-302018BA-A9D4-4CA8-9978-8E70511BB977
wdt:P433
3
wdt:P478
72
p:P356
wds:Q37415003-7E635D75-E04A-4A0C-9D19-6A4AC8BA3770
wdtn:P356
n11:J.EJPB.2009.02.014
wdt:P356
10.1016/J.EJPB.2009.02.014